CYP51A1 and Chagas disease: Assessment of combined treatment of antiparasitic drugs in human Chagas disease has been limited and clinical trials combining BNZ with CYP51 inhibitors have shown no benefit over BNZ monotherapy, highlighting the need to explore better combination partners (53–61).